Krystal Biotech (KRYS) Change in Acquisitions & Divestments (2019 - 2026)

Krystal Biotech has disclosed Change in Acquisitions & Divestments across 8 years of filings, most recently posting $103.6 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $103.6 million, up 16.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $390.4 million (up 20.6% YoY), and the FY2025 annual result was $375.6 million, up 25.83% from the prior year.
• Change in Acquisitions & Divestments came in at $103.6 million for Q1 2026 at Krystal Biotech, up from $85.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $161.2 million in Q2 2023 to a low of $24.0 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $88.8 million (2025), against an average of $90.5 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 4992.62% in 2022 and tumbled 58.83% in 2024, its largest moves.
• Krystal Biotech's Change in Acquisitions & Divestments stood at $104.1 million in 2022, then retreated by 28.33% to $74.6 million in 2023, then slipped by 18.9% to $60.5 million in 2024, then surged by 41.77% to $85.8 million in 2025, then gained by 20.79% to $103.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $103.6 million (Q1 2026), $85.8 million (Q4 2025), and $95.8 million (Q3 2025), per Business Quant data.